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Background 
Sebaceous-gland carcinoma is a rare malignancy. It is 
listed as one of  the defining features of  the Muir-Torre 
syndrome (1). Sebaceous-gland carcinoma occurs in the 
periocular region in about three quarters of  the patients. 
The majority of  the extraocular cases arise in the head and 
neck region. Cases occurring below the head and neck are 
extremely rare and tend to have a higher chance of  devel-
oping visceral malignancies, leading to poorer survival (1). 
The majority of  the sebaceous-gland carcinoma cases asso-
ciated with Muir-Torre syndrome actually occur outside the 
head and neck region, in most instances involving the torso 
and upper extremities (2). Although the FDG-avidity of  
sebaceous-gland carcinomas found in the head, neck, and 
breast region has been previously identified in case reports, 
this phenomenon is yet to be described in the lower 
extremity. 
Case report
 A 70-year-old Caucasian male with a known history of  
Muir-Torre syndrome presented with a recurrent lump in 
the medial aspect of  his left calf. He had previously under-
gone a resection of  sebaceous-gland carcinoma at this site. 
Manifestations of  Muir-Torre syndrome in his case (besides 
the sebaceous-gland carcinoma) included mismatch repair-
deficient cancer of  the colon and urothelial cancer of  the 
left renal pelvis, left ureter, and bladder for which he had 
undergone left-calf  wide local excision, colon resection, 
transurethral resection of  the bladder tumor, and left 
ureteronephrectomy. He reported cancer history in his un-
cle and father but could not recall the site or type. Medica-
tions included lorazepam, bupropion, seroquel, and trazo-
done for anxiety and depression. He was an ex-heavy 
smoker, but denied alcohol abuse or use of  recreational 
drugs. Vital signs were stable.  
The patient presented with a (third) recurrence of  the 
sebaceous-gland carcinoma in the previously excised loca-
tion. He was sent for an 18F-FDG PET/CT scan to rule 
out new or recurrent visceral malignancies and to assess the 
regional nodal status and possibility of  distant 
metastases. The noncontrast computerized tomographic 
(CT) scan demonstrated a 2.9 x 1.8 x 3.7-cm soft-tissue 
mass along the medial aspect of  the left calf  within the 
superficial subcutaneous soft tissues (Fig. 1). The 18F-FDG 
PET scan revealed intense pathologic uptake (SUVmax 
9.1) coregistering with this mass, consistent with biologic 
tumor activity. There were no other sites of  abnormal 18F-
FDG uptake (Figs. 2 and 3). The patient underwent a radi-
cal excision of  the lesion with sentinel lymph node lym-
phoscintigraphy and biopsy, followed by reconstructive 
surgery with placement of  a skin graft. Histopathology 
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confirmed a sebaceous-gland carcinoma measuring 6.8 x 
5.5 x 2.0 cm that was 0.25 mm from the deep (closest) sur-
gical margin. All margins and sentinel lymph nodes proved 
negative for carcinoma. The tumor mass was diagnosed as 
low-grade sebaceous-gland carcinoma (T2N0). The tumor 
was a nonencapsulated, infiltrative neoplasm composed of  
atypical epithelial cells with sebaceous differentiation, the 
latter with vacuolated cytoplasm and prominent nuclei, and 
displayed significant necrosis and mitoses. However, per-
ineural or vascular invasion was not seen (Fig. 4). 
About a month after resection, a postoperative irradia-
tion course was directed to the resection site and a small 
margin, with a total dose of  50 Gy in 25 treatments using a 
prescription isodose line of  90% with a 0.5 cm bolus.  
A total-body 18F-FDG PET- CT scan  three months 
postirradiation did not reveal any residual disease (Fig. 5), 
and the patient remains disease-free to date. 
Discussion
 Sebaceous-gland carcinoma is an uncommon and ag-
gressive malignancy (1). The malignant cell of  origin is 
derived from the adnexal epithelium (1). The etiology of  
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Fig. 2: Coregistration of transaxial CT images with 18FDG 
PET images. Intense pathological FDG uptake (SUV 9.1) is 
present on initial 18FDG PET examination coregistering with 
superficial soft-tissue mass, consistent with biologic tumor 
activity.
Fig. 3: Coregistration of coronal CT Images with 18FDG 
PET image. Intense pathological FDG uptake (SUV 9.1) is 
present on initial 18FDG PET examination coregistering 
with superficial soft-tissue mass, consistent with biologic 
tumor activity.
Fig. 1: Lower-extremity noncontrast, low-dose axial CT im-
age of lower extremities demonstrates 2.9 x 1.8 x 3.7-cm 
soft-tissue mass along medial aspect of left calf within the 
superficial subcutaneous soft tissues. The longest diameter 
in the coronal plane is 3.6 cm, in the sagittal plane 3.6 cm, 
and in the transaxial 3.2 cm.
Fig. 4: Pathological specimen. A. Well-differentiated seba-
ceous carcinoma composed of lobules and sheets of tumor 
cells with central necrosis (40 X). B. Individual cells have 
distinct cell membranes, clear to vacuolated cytoplasm, 
vesicular nuclei with prominent nucleoli and mitotic figures 
(400X).
sebaceous-gland carcinoma is not entirely understood. Rare 
cases are associated with familial genetic disorders. The 
median age at diagnosis is 72, and it is somewhat more 
prevalent in Caucasian men (3). Several risk factors for the 
development of  sebaceous-gland carcinoma have been 
proposed in various studies, including radiotherapy in chil-
dren with retinoblastoma, infection with high-risk human 
papilloma virus, and the overexpression of  p53 (4). Rare 
cases of  sebaceous-gland carcinoma are associated with 
Muir-Torre syndrome. The diagnostic criterion for Muir-
Torre syndrome requires the presence of  at least one vis-
ceral malignancy along with a sebaceous neoplasm (3), 
without having an environmental risk factor for sebaceous 
neoplasm. Of  all sebaceous neoplasms,  cutaneous seba-
ceous adenoma is the one most common encountered in 
Muir-Torre syndrome (5). Sebaceous-gland carcinoma is 
found only in 23% of  cases of  Muir-Torre syndrome (14). 
The development of  sebaceous neoplasms in Muir-Torre 
syndrome is related to a defective DNA mismatch-repair 
(MMR) system that leads to unchecked genetic aberrations, 
including loss of  tumor suppressor genes (6). Inactivation of 
both alleles of  an MMR gene as a result of  highly pene-
trant autosomal dominant mutations, most commonly in 
MLH1 and/or MSH2 genes, leads to defective mismatch 
repair, resulting in microsatellite instability (MSI). This MSI 
can result in frameshift mutations within the microsatellites 
containing tumor-suppressor genes (6). These mutations 
may interfere with gene-splicing sites, eventually leading to 
loss of  tumor-suppressor proteins (2). 
The MMR status may have a correlation with the site of  
development of  sebaceous-gland carcinoma. Although the 
majority of  cases affect the head and neck region, Singh et 
al (2), found that 92% of  the sebaceous tumors occurring in 
MMR-deficient patients, like our patient, occur outside the 
head and neck region, mainly in the trunk or upper ex-
tremities. However, what is unusual and thus interesting in 
our case of  sebaceous-gland carcinoma associated with 
Muir-Torre syndrome is the involvement of  the lower limb. 
A literature search found only 24 cases of  sebaceous-gland 
carcinoma involving the lower extremity, leading to the 
conclusion that a primary sebaceous-gland carcinoma in 
this region is a novel discovery (1). One case of  sebaceous-
gland carcinoma was reported in the left popliteal fossa (7), 
while another manuscript reported sebaceous-gland carci-
noma presenting as multiple ulcerated nodules and papules 
on the leg of  a 32-year-old male (8). Even more interesting 
is the fact that none of  these 24 cases were described to be 
associated with Muir-Torre syndrome.   
Another intriguing aspect of  this case is the FDG positiv-
ity of  the lower-extremity sebaceous-gland carcinoma. 
18FDG PET/CT has become a significant tool in cancer 
imaging for diagnosis, staging, and evaluation of  treatment 
response. In the case of  sebaceous-gland carcinoma, the 
rate of  nodal and distant metastatic disease approaches 
about 25% (9), and thus 18FDG PET/CT may have a po-
tential role in precisely defining the disease stage. However, 
as sebaceous-gland carcinoma is rare, there is very limited 
literature published on the utility of  18FDG PET/CT in 
sebaceous-gland carcinoma, and it is composed only of  
case reports that describe a handful of  cases. Baek et al. 
described 5 cases of  periocular sebaceous-gland carcinoma 
in which 18FDG PET/CT scan correctly identified 4 of  4 
cases of  regional lymph-node involvement, whereas 3 of  
these 4 were undetected with CT alone (10). Krishna et al. 
described two cases of  ocular sebaceous-gland carcinoma 
that were successfully staged with 18FDG PET/CT (11). In 
one case, pathological FDG uptake was noted in subman-
dibular, supraclavicular, mediastinal, and retroperitoneal 
lymph nodes (11).
There are even fewer reports describing use of  18FDG 
PET/CT in extraocular sebaceous-gland carcinoma. 
Bongu et al. described a case of  a biopsy-proven recurrent 
9-cm sebaceous-gland carcinoma on the back of  a 47-year-
old male that was intensely FDG-avid, with no other sites 
of  abnormal 18FDG uptake (12). Until now, only one pub-
lished report describes a case of  an FDG-avid upper-
extremity sebaceous-gland carcinoma. In this case of  a 70-
year-old female with an enlarging upper-arm sebaceous-
gland carcinoma, bone scintigraphy demonstrated in-
creased uptake in a large mass in the proximal humerus 
with central photopenia. The 18FDG PET/CT scan addi-
tionally found distal disease, undetected by other imaging 
studies. This included left-lung metastases as well as left 
sacroiliac articulation (13). 
As up to a third of  patients may experience recurrence 
post surgery despite excision with clear tumor margins of  5 
to 6 mm (14), radiotherapy is often employed, even though 
no comparison of  postoperative irradiation with surgery 
alone has been done (3). We also treated our patient with a 
course of  postoperative radiotherapy, and he remains with-
out recurrence to date. 
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Fig. 5. Subsequent coregistered 18FDG PET CT coronal 
image post excision and radiotherapy shows no residual 
areas of abnormal 18FDG uptake consistent with good 
treatment response.
To conclude, a novel presentation of  recurring 
sebaceous-gland carcinoma of  the lower extremity (shown 
to be FDG-avid) was seen in a male patient with Muir-
Torre syndrome. Multiple surgeries and radiotherapy were 
required to successfully treat the sebaceous-gland carci-
noma as confirmed (post treatment) with 18FDG PET/CT 
scan, which demonstrated resolution to a non-18FDG-avid 
status. To our knowledge, sebaceous-gland carcinomas have 
rarely been reported in the extremities (especially the lower 
extremity). Moreover, we present the first case of  an 
18FDG-avid sebaceous-gland carcinoma of  the lower 
extremity.  
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